patients with suspected or confirmed severe infection caused by gram-positive cocci
Conditions
Interventions
Conventional dose group:daptomycin 6 mg/kg Q24h
High dose group:daptomycin 10 mg/kg Q24h
Sponsors
The Second Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Confirmed patients with severe infection caused gram positive coccus: Methicillin-resistant Staphylococcus aureus, Methicillin-resistant Staphylococcus epidermidis, Vancomycin-resistant Enterococcus bloodstream infections; Skin and soft tissue infections, bone and joint infections, infective endocarditis, neutropenia with fever, intracranial infections; 2.Suspected patients with severe infection caused by gram positive coccus:bloodstream infection, skin and soft tissue infection, bone and joint infection, infective endocarditis, neutropenia with fever, intracranial infection; If the broad-spectrum antibiotic treatment fails, Gram-positive coccal infection is considered; 3.Aged >= 18 years; 4.Informed consent is signed.
Exclusion criteria
Exclusion criteria: 1. Gram-positive staphylococcus aureus pneumonia; 2. Pregnancy or lactation; 3. Has used daptomycine before inclusion; 4. Allergy to daptomycine; 5. Included in other clinical studies; 6. Quit during the study; 7. Creatinine clearance 30 ml/min or less, or the use of peritoneal dialysis, or intermittent hemodialysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of successful clinical treatment;The incidence of acute adverse events;Plasma concentration of datoramycin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Early clinical response;responses to microorganisms;Length of ICU stay;Minimum Inhibitory Concentration (MIC) of Datoromycin;ABCB1 mononucleic acid variants that affect datomycin metabolism; | — |
Countries
China
Contacts
Public ContactHongliang Wang
The Second Affiliated Hospital of Harbin Medical University
Outcome results
None listed